Improvement in treatment and outcome of pancreatic ductal adenocarcinoma in north China. (Q51040515)

27 March 2018

title

Improvement in treatment and outcome of pancreatic ductal adenocarcinoma in north China. (English)

1 reference

27 March 2018

invasive ductal carcinoma

1 reference

1 reference

pancreatic ductal adenocarcinoma

inferred from title

1 reference

pancreatic ductal carcinoma

inferred from title

1 reference

Yong Chen

1

1 reference

27 March 2018

JiHui Hao

2

1 reference

27 March 2018

WeiDong Ma

3

1 reference

27 March 2018

Yong Tang

4

1 reference

27 March 2018

ChunTao Gao

5

1 reference

27 March 2018

XiShan Hao

6

1 reference

27 March 2018

publication date

12 April 2011

1 reference

27 March 2018

Journal of Gastrointestinal Surgery

published in

1 reference

27 March 2018

volume

15

1 reference

27 March 2018

issue

6

1 reference

27 March 2018

page(s)

1026-1034

1 reference

27 March 2018

https://scigraph.springernature.com/pub.10.1007/s11605-011-1493-y

exact match

0 references

cites work

A cancer incidence survey in Tianjin: the third largest city in China-between 1981 and 2000.

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

21 January 2018

International variation

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

Pancreatic cancer: from bench to 5-year survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

The National Cancer Data Base report on pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

One thousand consecutive pancreaticoduodenectomies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

Intraoperative transfusion: is it a real prognostic factor of periampullary cancer following pancreatoduodenectomy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

Effect of blood transfusion on outcome after pancreaticoduodenectomy for exocrine tumour of the pancreas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

21 January 2018

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

Early detection of pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

Is pancreatectomy with arterial reconstruction a safe and useful procedure for locally advanced pancreatic cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

The impact of curative intent surgery on the survival of pancreatic cancer patients: a U.S. Population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

Biological approaches to therapy of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-011-1493-Y

Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy

21 January 2018

1 reference

12 December 2020

Clinical implications of combined portal vein resection as a palliative procedure in patients undergoing pancreaticoduodenectomy for pancreatic head carcinoma

1 reference

12 December 2020

Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas

1 reference

12 December 2020

1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience

1 reference

12 December 2020

Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings

1 reference

12 December 2020

Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma

1 reference

12 December 2020

Factors associated with survival after surgical resection in Chinese patients with ductal adenocarcinoma of the pancreatic head

1 reference

12 December 2020

Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers

1 reference

12 December 2020

Treatment and survival in 13560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: An epidemiological study

1 reference

12 December 2020

Tumour markers in gastrointestinal cancers--EGTM recommendations. European Group on Tumour Markers

1 reference

12 December 2020

Prognostic factors for survival after extended pancreatectomy for pancreatic head cancer: influence of resection margin status on survival

1 reference

12 December 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

12 December 2020

Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia

1 reference

12 December 2020

Recurrence after resection for ductal adenocarcinoma of the pancreas

1 reference

12 December 2020

10.1007/S11605-011-1493-Y

Identifiers

DOI

1 reference

27 March 2018

PubMed ID

21484493

1 reference

27 March 2018